Obalon Therapeutics (NASDAQ:OBLN) Earns Daily Coverage Optimism Rating of 0.13

Media coverage about Obalon Therapeutics (NASDAQ:OBLN) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Obalon Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.4158428431622 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have effected Accern’s scoring:

Obalon Therapeutics (NASDAQ OBLN) opened at $4.36 on Tuesday. The company has a market capitalization of $99.52 and a PE ratio of -2.26. Obalon Therapeutics has a 1-year low of $3.40 and a 1-year high of $13.18. The company has a quick ratio of 8.65, a current ratio of 8.78 and a debt-to-equity ratio of 0.21.

A number of equities research analysts have recently issued reports on the company. BTIG Research lowered their target price on Obalon Therapeutics from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, November 6th. Zacks Investment Research lowered Obalon Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. UBS Group lowered their target price on Obalon Therapeutics from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, November 10th. Canaccord Genuity reiterated a “buy” rating and issued a $11.00 target price (down previously from $15.00) on shares of Obalon Therapeutics in a research note on Monday, January 22nd. They noted that the move was a valuation call. Finally, Northland Securities reiterated a “sell” rating and issued a $4.00 target price on shares of Obalon Therapeutics in a research note on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $10.90.

COPYRIGHT VIOLATION WARNING: “Obalon Therapeutics (NASDAQ:OBLN) Earns Daily Coverage Optimism Rating of 0.13” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/13/obalon-therapeutics-obln-receives-media-sentiment-rating-of-0-13.html.

About Obalon Therapeutics

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

Insider Buying and Selling by Quarter for Obalon Therapeutics (NASDAQ:OBLN)

Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply